Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs
Season 2, Episode 32, Jun 20, 02:00 PM
Share
Subscribe
Episode Description
In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they delve into emerging clinical data on next-generation, HER2-selective tyrosine kinase inhibitors. Through expert insights and discussion of recent trial findings, this conversation highlights how novel targeted therapies are reshaping treatment strategies and providing new hope for patients with HER2-mutant NSCLC.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corporation; Janssen Biotech, Inc; and Partner Therapeutics, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 3462
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Today’s faculty are:
Millie Das, MD
Chief, Oncology, VA Palo Alto Health Care System
Clinical Professor, Stanford University
Palo Alto, CA
Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.
Eric K. Singhi, MD
Assistant Professor
Department of General Oncology and Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Regeneron.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date
June 20, 2025
Expiration Date
June 20, 2026
In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they delve into emerging clinical data on next-generation, HER2-selective tyrosine kinase inhibitors. Through expert insights and discussion of recent trial findings, this conversation highlights how novel targeted therapies are reshaping treatment strategies and providing new hope for patients with HER2-mutant NSCLC.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corporation; Janssen Biotech, Inc; and Partner Therapeutics, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 3462
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Today’s faculty are:
Millie Das, MD
Chief, Oncology, VA Palo Alto Health Care System
Clinical Professor, Stanford University
Palo Alto, CA
Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.
Eric K. Singhi, MD
Assistant Professor
Department of General Oncology and Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Regeneron.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date
June 20, 2025
Expiration Date
June 20, 2026